Icosavax, Inc. (ICVX) News

Icosavax, Inc. (ICVX): $11.13

0.22 (+2.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICVX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter ICVX News Items

ICVX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ICVX News Highlights

  • For ICVX, its 30 day story count is now at 2.
  • Over the past 15 days, the trend for ICVX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ICVX are ADD and PATH.

Latest ICVX News From Around the Web

Below are the latest news stories about ICOSAVAX INC that investors may wish to consider to help them evaluate ICVX as an investment opportunity.

‘With Risk Comes Opportunity’: Oppenheimer Suggests 2 Stocks to Buy, Including One With 170% Upside Potential

While the overall stock market direction so far this year remains up, the path ahead still presents plenty of potential headwinds. Inflation has yet to be properly tamed, the geopolitical map remains uncertain with Russia’s invasion of Ukraine still ongoing and Covid variants could reappear at any time. Add in the prospect for a fiery battle in Congress around raising the debt ceiling, and Oppenheimer’s Chief Investment Strategist John Stoltzfus thinks market volatility is “unlikely to leave the

Yahoo | January 27, 2023

Icosavax (NASDAQ:ICVX) adds US$100m to market cap in the past 7 days, though investors from a year ago are still down 38%

It is a pleasure to report that the Icosavax, Inc. ( NASDAQ:ICVX ) is up 200% in the last quarter. But in truth the...

Yahoo | January 12, 2023

Icosavax Provides Corporate Update and Anticipated Milestones for 2023

- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of IVX-A12 (a bivalent of IVX-121 for RSV and IVX-241 for hMPV) progressing and on track for topline results in mid-2023 - - IVX-A12 Phase 2 initiation expected in 2H 2023 - SEATTLE, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative v

Yahoo | January 6, 2023

The Year of the Tripledemic

COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of whic...

Yahoo | January 3, 2023

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

Yahoo | December 16, 2022

Dow Sheds Over 670 Points On Reignited Recession Fears

Disappointing retail sales data and a fresh interest rate hike are still weighing on stocks this afternoon, as traders fear that the Federal Reserve's hawkish stance could push the economy into a recession.

TalkMarkets.com | December 15, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | December 15, 2022

Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says

Icosavax Inc (NASDAQ: ICVX) provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV), demonstrating a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121. William Blair analyst thinks the best comparison for IVX-121 is Pfizer Inc’s (NYSE: PFE) RSVpreF vaccine. The estimated percentage of retained titers for RSV-A from 28 days to 180 days post-immunization

Yahoo | December 14, 2022

Icosavax Highlights Six Months Durability Data For Respiratory Syncytial Virus Vaccine Candidate

Icosavax Inc (NASDAQ: ICVX) provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121. IVX-121 continued to be generally well-tolerated, with no safety concerns observed in this six-month follow-up and no vaccine-related serious adverse events (SAEs). In these day 180 immunoge

Yahoo | December 14, 2022

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Figure 1 - RSV-A nAB, GMT Expressed in IU/mL Figure 1 - RSV-A nAB, GMT Expressed in IU/mL - In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults - - First clinical evidence of potential differentiation on durability with company’s VLP platform technology - - IVX-121 continues to be generally well tolerated with no safety concerns observed

Yahoo | December 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5454 seconds.